+ Equity
Unifying AI and biotechnology for drug discovery
Open for applications
Unifying AI and biotechnology for drug discovery
21-100 employees
Open for applications
+ Equity
21-100 employees
To transform small molecule drug discovery to solve critical patient needs.
Jump to section
To transform small molecule drug discovery to solve critical patient needs.
Few candidates hear
back within 2 weeks
Genesis Therapeutics is at the forefront of advancing drug creation to foster better healthcare outcomes. the company offers an AI-powered molecule discovery platform, known as GEMS, designed to empower medical researchers. By seamlessly integrating AI with biotech, GEMS leverages deep learning and molecular simulations to explore uncharted territories within chemical space, unveiling novel opportunities for functional drugs.
Boasted to be the "industry's most advanced molecular AI platform", GEMS accelerates the discovery of small molecules while also enhancing potency and selectivity. This breakthrough capability not only expedites the development process but also paves the way for creating medications targeting previously inaccessible domains.
With significant funding backing its endeavours, Genesis Therapeutics is poised to transition into clinical testing. Moreover, the company aims to broaden the scope of its platform, extending its reach to encompass a wider array of therapeutic targets.
Kirsty
Company Specialist
Aug 2023
$224.1m
SERIES B
Dec 2020
$52m
SERIES A
This company has top investors
Founders
Evan Feinberg
(CEO)PhD Graduate from Stanford, where they were an Algorithm Developer, collaborating with the Office of Technology Licensing to develop BraneRank (which uses graph substructures to rank search results). Was then a Deep Learning Consultant for Merck for 11 months.
Ben Sklaroff
(CTO)Graduated from UC Berkeley with a degree in Electrical Engineering and Computer Science. Worked at Markforged for 3 years, ultimately as Director of Software Engineering.